|
News FDA approves Inlyta to treat patients with a type of advanced kidney cancer
The U.S. Food and Drug Administration approved Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer. |
|
News FDA approves Sutent for rare type of pancreatic cancer
The U.S. Food and Drug Administration approved Sutent (sunitinib) to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body (metastatic). |
|
News Third Phase III Study of Avastin-Based Regimen Met Primary Endpoint in Ovarian Cancer
Genentech, a member of the Roche Group, announced that OCEANS, a Phase III study evaluating Avastin® (bevacizumab) in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of Avastin alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint. |
|
News Genentech Provides Update on Avastin for Metastatic Breast Cancer Following Reviews in Europe and the United States
Genentech, a member of the Roche Group, confirmed that following the reviews of Avastin® (bevacizumab) in metastatic breast cancer by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), the following regulatory announcements were made by the individual health authorities: |
|
Article Hypernephroma (Kidney Cancer)
You have two kidneys. They are fist-sized organs on either side of your backbone above your waist. |
|
Article Kidney Cancer Association
The Kidney Cancer Association (KCA) is a charitable organization made up of patients, family members, physicians, researchers, and other health professionals globally. |
